StockIQpro
NASDAQ:MPLT

MapLight Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

MapLight Therapeutics, Inc. reported net income of −$161.2M in fiscal 2025. Free cash flow was −$138.6M, and the diluted share count rose 1079.2%.Summary generated from MapLight Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−121.7%
Debt / equityn/a
Free cash flow−$138.6M
FCF marginn/a
Share count change+1079.2%

Financials

Fiscal years, $M
Item20242025
Revenuen/an/a
Operating income−83−169
Net income−78−161
Free cash flow−80−139

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations